JP2015512433A5 - - Google Patents

Download PDF

Info

Publication number
JP2015512433A5
JP2015512433A5 JP2015503848A JP2015503848A JP2015512433A5 JP 2015512433 A5 JP2015512433 A5 JP 2015512433A5 JP 2015503848 A JP2015503848 A JP 2015503848A JP 2015503848 A JP2015503848 A JP 2015503848A JP 2015512433 A5 JP2015512433 A5 JP 2015512433A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
weight
disintegrant
diluent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015503848A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512433A (ja
JP6320990B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/056867 external-priority patent/WO2013149987A1/en
Publication of JP2015512433A publication Critical patent/JP2015512433A/ja
Publication of JP2015512433A5 publication Critical patent/JP2015512433A5/ja
Application granted granted Critical
Publication of JP6320990B2 publication Critical patent/JP6320990B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015503848A 2012-04-04 2013-04-02 Ｃｃｒ３アンタゴニストを含む医薬製剤 Active JP6320990B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12163078.4 2012-04-04
EP12163078 2012-04-04
PCT/EP2013/056867 WO2013149987A1 (en) 2012-04-04 2013-04-02 Pharmaceutical formulations comprising ccr3 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018072309A Division JP6700332B2 (ja) 2012-04-04 2018-04-04 Ｃｃｒ３アンタゴニストを含む医薬製剤

Publications (3)

Publication Number Publication Date
JP2015512433A JP2015512433A (ja) 2015-04-27
JP2015512433A5 true JP2015512433A5 (enExample) 2016-06-02
JP6320990B2 JP6320990B2 (ja) 2018-05-09

Family

ID=49292482

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015503848A Active JP6320990B2 (ja) 2012-04-04 2013-04-02 Ｃｃｒ３アンタゴニストを含む医薬製剤
JP2018072309A Active JP6700332B2 (ja) 2012-04-04 2018-04-04 Ｃｃｒ３アンタゴニストを含む医薬製剤
JP2020080024A Pending JP2020143080A (ja) 2012-04-04 2020-04-30 Ｃｃｒ３アンタゴニストを含む医薬製剤
JP2022026735A Pending JP2022081524A (ja) 2012-04-04 2022-02-24 Ｃｃｒ３アンタゴニストを含む医薬製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018072309A Active JP6700332B2 (ja) 2012-04-04 2018-04-04 Ｃｃｒ３アンタゴニストを含む医薬製剤
JP2020080024A Pending JP2020143080A (ja) 2012-04-04 2020-04-30 Ｃｃｒ３アンタゴニストを含む医薬製剤
JP2022026735A Pending JP2022081524A (ja) 2012-04-04 2022-02-24 Ｃｃｒ３アンタゴニストを含む医薬製剤

Country Status (31)

Country Link
US (3) US10213421B2 (enExample)
EP (3) EP3970693B1 (enExample)
JP (4) JP6320990B2 (enExample)
KR (2) KR102338465B1 (enExample)
CN (1) CN104203213A (enExample)
AR (1) AR090596A1 (enExample)
AU (1) AU2013245028B2 (enExample)
BR (1) BR112014024479A8 (enExample)
CA (1) CA2869058C (enExample)
CL (1) CL2014002524A1 (enExample)
CY (1) CY1121137T1 (enExample)
DK (2) DK2833864T3 (enExample)
EA (1) EA027627B1 (enExample)
ES (3) ES2715844T3 (enExample)
HR (1) HRP20190069T1 (enExample)
HU (2) HUE056943T2 (enExample)
IL (1) IL234299A (enExample)
IN (1) IN2014DN07082A (enExample)
LT (1) LT2833864T (enExample)
MX (1) MX358307B (enExample)
NZ (1) NZ628993A (enExample)
PH (1) PH12014502241A1 (enExample)
PL (2) PL3524230T3 (enExample)
PT (2) PT2833864T (enExample)
RS (1) RS58360B1 (enExample)
SI (1) SI2833864T1 (enExample)
SM (1) SMT201900121T1 (enExample)
TR (1) TR201821285T4 (enExample)
TW (1) TW201400115A (enExample)
UY (1) UY34730A (enExample)
WO (1) WO2013149987A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
NZ757769A (en) 2017-04-05 2025-10-31 Alkahest Inc Methods and compositions for treating retina-associated disease using ccr3-inhibitors
KR20190131078A (ko) * 2017-04-05 2019-11-25 알카헤스트 인코포레이티드 Ccr3-억제제를 사용한 노화 관련 장애 치료를 위한 방법 및 조성물
KR20200067859A (ko) * 2017-10-13 2020-06-12 알카헤스트 인코포레이티드 Ccr3-억제제를 사용한 소양증, 건조증, 및 관련 질환을 치료하기 위한 방법 및 조성물
CA3097083A1 (en) 2018-05-15 2019-11-21 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase
MX2021002967A (es) * 2018-09-26 2021-08-11 Alkahest Inc Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores ccr3.
JPWO2022045226A1 (enExample) 2020-08-27 2022-03-03
CA3221177A1 (en) 2021-11-01 2023-05-04 Meghan Kerrisk Campbell Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7907121L (sv) 1979-08-27 1981-02-28 Astra Laekemedel Ab Ftalimidinderivat
US4992277A (en) 1989-08-25 1991-02-12 Schering Corporation Immediate release diltiazem formulation
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
IL116539A (en) * 1995-01-06 2002-02-10 Noven Pharma Preparations given through the skin of unstable anti-acid drugs
JP2001524131A (ja) * 1997-05-09 2001-11-27 セイジ、ファーマスーティカルズ、インク 安定な経口医薬品剤形
AU2335699A (en) 1998-01-21 1999-08-09 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
EP1052992A1 (en) 1998-02-02 2000-11-22 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US20040082788A1 (en) * 2002-07-08 2004-04-29 Chemgenex Therapeutics, Inc. Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof
EP1668035A2 (en) 2003-09-11 2006-06-14 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
WO2005040129A2 (en) 2003-10-24 2005-05-06 F. Hoffmann-La Roche Ag Ccr3 receptor antagonists
EP1687294B1 (en) 2003-11-17 2014-05-21 Boehringer Ingelheim International GmbH Novel piperidine-substituted indoles-or hetero-derivatives thereof and their use as modulators of chemokine receptor (ccr-3)
CA2554465A1 (en) 2004-02-05 2005-08-25 Schering Corporation Piperidine derivatives useful as ccr3 antagonists
JP2006137718A (ja) 2004-11-12 2006-06-01 Astellas Pharma Inc インドール若しくはインダゾール誘導体
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
JP3701964B1 (ja) 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
ATE531706T1 (de) 2005-04-30 2011-11-15 Boehringer Ingelheim Int Neue piperidin-substituierte indole und ihre verwendung als ccr-3-modulatoren
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
EP2059515A2 (en) 2006-04-12 2009-05-20 Pfizer Limited Pyrrolidine derivatives as modulators of chemokine ccr5 receptors
ATE524461T1 (de) 2006-10-27 2011-09-15 Boehringer Ingelheim Int Neue substituierte piperidylpropanthiole
EP2079725B1 (en) 2006-10-27 2011-12-14 Boehringer Ingelheim International GmbH Piperidyl-propane-thiol ccr3 modulators
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
US8008092B2 (en) 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
NZ600010A (en) 2007-10-24 2013-11-29 Generics Uk Ltd Novel crystalline forms of bosentan, processes for their preparation and uses thereof
TW201000446A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
WO2010052727A1 (en) * 2008-11-04 2010-05-14 Ideal Cures Private Limited High performance film coating compositions
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
NZ595797A (en) * 2009-04-22 2014-03-28 Axikin Pharmaceuticals Inc 2,5-disubstituted arylsulfonamide ccr3 antagonists
JP5847702B2 (ja) 2009-04-22 2016-01-27 アクシキン ファーマシューティカルズ インコーポレーテッド ２，５−二置換アリールスルホンアミドｃｃｒ３アンタゴニスト
WO2011083402A2 (en) * 2010-01-11 2011-07-14 Muneera Mohamed Shafee Immediate release compositions of acid labile drugs
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists

Similar Documents

Publication Publication Date Title
JP2015512433A5 (enExample)
JP6700332B2 (ja) Ｃｃｒ３アンタゴニストを含む医薬製剤
JP2018021082A5 (enExample)
JP6487599B2 (ja) エスシタロプラム医薬組成物
EA039006B1 (ru) Ингибиторы тирозинкиназы
TWI750143B (zh) 含有2-{4-[n-(5,6-二苯基吡-2-基)-n-異丙基胺基]丁基氧基}-n-(甲基磺醯基)乙醯胺之醫藥組合物
CA3019499A1 (en) Film-coated tablet having high chemical stability of active ingredient
JP2020158435A (ja) リナグリプチン含有医薬組成物及びその製造方法、並びにリナグリプチン含有医薬組成物の品質の向上方法
KR101446129B1 (ko) 프란루카스트-함유 고형 제제의 제조방법
JP2017031117A (ja) 光安定性を向上した、イミダフェナシン製剤
WO2016079687A1 (en) Oral pharmaceutical composition of teriflunomide
JPWO2009123169A1 (ja) アミド誘導体含有医薬組成物
EP1968593B1 (en) Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
JP2016155777A (ja) モンテルカスト又はその塩を含む組成物
WO2015069203A1 (en) Capsule comprising rupatadine fumarate and montelukast sodium
WO2011012987A1 (en) Pharmaceutical composition of isoniazid
JP7271869B2 (ja) レボセチリジン含有錠剤
JP2014114243A (ja) 安定な固形製剤の製造方法
JP2016222651A (ja) ミグリトール含有口腔内崩壊錠
EP3731822A1 (en) Oral pharmaceutical compositions of dabigatran
JP2019073445A (ja) アプレピタントを有効成分とする医薬組成物
JP6340270B2 (ja) 安定なモンテルカストナトリウム含有経口固形医薬組成物、その製造方法、およびモンテルカストナトリウムの類縁物質生成抑制方法
CA3038620A1 (en) Pharmaceutical compositions of 5-ht6 antagonist
JP6336651B1 (ja) 化学的安定性が改善されたエソメプラゾール塩を含有する錠剤
US20210346374A1 (en) Pharmaceutical compositions of 5-ht6 receptor antagonist